Published in AJR Am J Roentgenol on November 01, 2013
Positron emission tomography to assess hypoxia and perfusion in lung cancer. World J Clin Oncol (2014) 0.79
Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity. EJNMMI Res (2015) 0.75
Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone). Semin Nucl Med (2015) 0.75
Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2015) 0.75
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol (1997) 3.25
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer (2005) 2.12
Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res (2009) 1.88
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res (2001) 1.85
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2008) 1.51
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med (2001) 1.51
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer (2005) 1.48
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem (2008) 1.26
Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med (2009) 1.21
The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal (2007) 1.20
High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol (1999) 1.15
Comparison of 1H blood oxygen level-dependent (BOLD) and 19F MRI to investigate tumor oxygenation. Magn Reson Med (2009) 1.10
Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med (2000) 1.01
Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res (2007) 1.00
Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res (2004) 1.00
Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med (1990) 0.99
Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep (2008) 0.88
PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol (2008) 0.88
Pulmonary Langerhans cell histiocytosis and other pulmonary histiocytic diseases: a review. Arch Pathol Lab Med (2008) 0.80
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 6.99
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell (2005) 5.75
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell (2007) 3.50
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt (2005) 2.94
Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol (2005) 2.82
A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol (2010) 2.79
The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys (2005) 2.70
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev (2007) 2.15
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03
The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer (2010) 1.97
Thresholds for thermal damage to normal tissues: an update. Int J Hyperthermia (2011) 1.86
Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol (2003) 1.83
Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res (2005) 1.81
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst (2006) 1.79
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys (2005) 1.73
A dual-emissive-materials design concept enables tumour hypoxia imaging. Nat Mater (2009) 1.72
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
A novel rodent mammary window of orthotopic breast cancer for intravital microscopy. Microvasc Res (2003) 1.69
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med (2006) 1.65
A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med (2002) 1.65
Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res (2007) 1.64
Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res (2005) 1.63
Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 1.62
In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat Protoc (2011) 1.62
The pervasive presence of fluctuating oxygenation in tumors. Cancer Res (2008) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther (2002) 1.58
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer (2003) 1.56
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci U S A (2006) 1.54
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One (2012) 1.53
Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng (2004) 1.52
Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia (2006) 1.52
Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res (2007) 1.51
Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res (2004) 1.50
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer (2005) 1.48
Erythropoietin biology in cancer. Clin Cancer Res (2006) 1.48
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys (2005) 1.48
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys (2007) 1.46
Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res (2008) 1.42
Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys (2003) 1.42
Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids (2010) 1.41
Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys (2007) 1.40
Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol (2002) 1.40
Vaccine Therapy, Oncolytic Viruses, and Gliomas. Oncology (Williston Park) (2016) 1.38
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38
Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res (2006) 1.37
Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A (2006) 1.36
Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res (2006) 1.34
Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res (2004) 1.33
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A (2003) 1.32
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. Brain Behav Immun (2012) 1.31
Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med (2011) 1.31
Lipophilicity of potent porphyrin-based antioxidants: comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins. Free Radic Biol Med (2009) 1.30
Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res (2005) 1.29
Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther (2004) 1.28
Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res (2007) 1.27
Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res (2006) 1.26
Characterization of a 137Cs irradiator from a new perspective with modern dosimetric tools. Health Phys (2009) 1.26
Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation. Free Radic Res (2007) 1.25
Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res (2004) 1.24
A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. Int J Radiat Oncol Biol Phys (2006) 1.24
Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer (2005) 1.23
Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res (2004) 1.21
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol (2011) 1.21
The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal (2007) 1.20
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med (2004) 1.20
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One (2007) 1.19
Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood (2007) 1.19
Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol (2010) 1.19
Longitudinal optical imaging of tumor metabolism and hemodynamics. J Biomed Opt (2010) 1.17
Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int J Hyperthermia (2011) 1.17
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res (2011) 1.17
Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med (2009) 1.17
Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol (1985) (2009) 1.17
Optical imaging of tumor hypoxia dynamics. J Biomed Opt (2011) 1.16
CEM43°C thermal dose thresholds: a potential guide for magnetic resonance radiofrequency exposure levels? Eur Radiol (2013) 1.15
Molecular imaging of hypoxia. J Nucl Med (2011) 1.15
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther (2007) 1.14
Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J (2011) 1.14
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med (2011) 1.14
New PEG-ylated Mn(III) porphyrins approaching catalytic activity of SOD enzyme. Dalton Trans (2005) 1.12
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys (2004) 1.12
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10